to obtain crystallization was unsuccessful. IR ( KBr ) 3330 $\left(\mathrm{NH}_{2}\right), 1560(\mathrm{NH}), 1470,1380,1150,1020 \mathrm{cml}^{-1}$.

2-Bis(2-chloroethyl)amino-2-oxo-6-(5 $\alpha$-cholestanyl)-1,3,2-oxazaphosphorinane (1a and 1b). A crude 1.7 g ( 3.9 mmol ) of 4 and 1.0 g ( 3.9 mmol ) of bis( 2 -chloroethyl) phosphoramidic dichloride (5) was dissolved in $160 \mathrm{~m} /$ of anhydrous THF, and added 0.79 m ( 7.8 mmol ) of anhydrous $\mathrm{Et}_{3} \mathrm{~N}$. The reaction mixture was vigorously stirried for 24 hrs, and the $\mathrm{Et}_{3} \mathrm{~N} \cdot \mathrm{HCl}$ formed was filtered. The filtrate was evaporated in vaccuo and the residue was chromatographed on silica gel using EtOAc: $\mathrm{CH}_{2} \mathrm{Cl}_{2}$ : Hexane (2:2:1) to give fractions containing faster eluting $\mathbf{1 a}$ and slower eluting $\mathbf{1 b}$ ( $1 \mathrm{a}: \mathbf{1 b}=1: 1.2 ; 1.2 \mathrm{~g} ; 58 \%$ yield). For 1a: mp. $192-194^{\circ} \mathrm{C}$; ${ }^{1} \mathrm{H}-\mathrm{NMR}\left(\mathrm{CDCl}_{3}\right) \delta 3.61\left(\mathrm{t}, J=7.40,4 \mathrm{H}, 2 \times-\mathrm{NCH}_{2} \mathrm{CH}_{2} \mathrm{Cl}\right)$, $3.25-3.50\left(\mathrm{~m}, 4 \mathrm{H}, 2 \times-\mathrm{NCH}_{2} \mathrm{CH}_{2} \mathrm{Cl}\right), 3.19\left(\mathrm{~m}, 2 \mathrm{H},-\mathrm{NHCH}_{2}-\right.$ $\mathrm{CH}_{2}$ ), 2.73 (br s, $1 \mathrm{H}, \mathrm{NH}$ ), 2.12 (m, $2 \mathrm{H},-\mathrm{NHCH}_{2} \mathrm{CH}_{2}-$ ), $\quad 0.6-2.0$ ( $\mathrm{m}, \mathrm{H}$ steroid); ${ }^{13} \mathrm{C}-\mathrm{NMR}\left(\mathrm{CDCl}_{3}\right) 884.9$ (d, $\overline{\mathrm{J} . \mathrm{P} .}=7.8$, spiro carbon), 493 (d, $\left.J_{\mathrm{CP}}=3.0,2 \times-\mathrm{NCH}_{2} \mathrm{CH}_{2} \mathrm{Cl}\right), 42.5\left(2 \times-\mathrm{NCH}_{2}\right.$ $\left.\mathrm{CH}_{2} \mathrm{Cl}\right), 41.9\left(\mathrm{~d}, \mathrm{~J}_{\mathrm{CP}}=8.5,-\mathrm{NHCH}_{2} \mathrm{CH}_{2}\right.$-), $36.0\left(-\mathrm{NHCH}_{2} \mathrm{CH}_{2}\right.$-), $12.0,12.1,18.7,21.3,22.5,22.8,23.8,24.2,28.0,28.2,28.5,31.9$, $32.0,35.5,35.8,36.0,36.2,38.1,39.5,40.0,42.5,42.6,43.7,54.5$, 56.3 , and 56.5 (steroid carbons); ${ }^{34}$ P-NMR $\left(\mathrm{CDCl}_{3}\right) ~ \delta 10.25$; Mass (FAB) (m/z) $618(\mathrm{M}+1)$; Anal. Calcd. for $\mathrm{C}_{33} \mathrm{H}_{59} \mathrm{~N}_{2} \mathrm{O}_{2} \mathrm{PCl}_{2}: \mathrm{C}$, 64.17; H, 9.62; N, 4.53. Found: C, 64.09; H, 9.79; N, 4.32. For lb: mp. $178-180^{\circ} \mathrm{C} ;{ }^{1} \mathrm{H}-\mathrm{NMR}\left(\mathrm{CDCl}_{3}\right) \delta 3.60(\mathrm{t}, J=6.9,4 \mathrm{H}, 2$ $\mathrm{x}-\mathrm{NCH}_{2} \mathrm{CH}_{2} \mathrm{Cl}$ ), $3.28-3.54\left(\mathrm{~m}, 4 \mathrm{H}, 2 \times-\mathrm{NCH}_{2} \mathrm{CH}_{2} \mathrm{Cl}\right), 3.19(\mathrm{~m}$, $2 \mathrm{H},-\mathrm{NHCH}_{2} \mathrm{CH}_{2}$ -, 2.50 (br d, $1 \mathrm{H}, \mathrm{NH}$ ), 2.13 ( $\mathrm{m}, 2 \mathrm{H},-\mathrm{NHCH}_{2}$ $\mathrm{CH}_{2}$-), $0.6-2.0$ (m, H steroid); ${ }^{3} \mathrm{C}$-NMR ( $\mathrm{CDCl}_{3}$ ) $\delta 84.7$ (d, $J_{\mathrm{c} . \mathrm{P} .}=$ 7.8 , spiro carbon), 49.4 (d, $J_{C P}=4.3,2 \times-\mathrm{NCH}_{2} \mathrm{CH}_{2} \mathrm{Cl}$ ), 42.5 ( $2 \mathrm{x}-\mathrm{NCH}_{2} \mathrm{CH}_{2} \mathrm{Cl}$ ), 35.0 (d, $J_{\mathrm{CP} .}=7.4,-\mathrm{NHCH}_{2} \mathrm{CH}_{2}$ ), 35.8 ( $-\mathrm{NH}-$ $\mathrm{CH}_{2} \mathrm{CH}_{2}-$ ), 12.0, 12.1, 18.7, 21.1, 22.5, 22.8, 23.8, 24.2, 28.0, $28.5,32.0,35.4,35.7,35.9,36.2,38.7,39.4,40.0,42.5,42.6$, 43.9, 54.5, 56.3, and 56.5 (steroid carbons); ${ }^{31} \mathrm{P}-\mathrm{NMR}\left(\mathrm{CDCl}_{3}\right)$ $\delta 10.48$; Mass ( FAB ) $(\mathrm{m} / \mathrm{z}) 618(\mathrm{M}+1)$; Anal. Calcd. for $\mathrm{C}_{33}-$ $\mathrm{H}_{59} \mathrm{~N}_{2} \mathrm{O}_{2} \mathrm{PCl}_{2}: \mathrm{C}, 64.17 ; \mathrm{H}, 9.62: \mathrm{N}, 4.53$. Found: C, 64.32; H, 9.98; N, 4.49.

Acknowledgement. The authers wish to express their appreciation to professor Hae-Young Chung, College of Pharmacy, Pusan National University for the antitumor assay. The present study was supported in part by the Basic Science Research Institude Program, Ministry of Education, 1991 (BSRI-91-308).

## References

1. (a) N. E. Sladek, Pherm. Ther., 37, 301 (1988); (b) R. F. Borch and R. R. Valente, J. Med. Chem., 34, 3052 (1991) and references cited therein.
2. Bulky acetonitrile nucleophile encounters the 3,5 -diaxial hydrogens on the trajectroy for axial attack. Therefore, bulky group nuclophilic addition on cholestanone (2) yielded equatorial attacked product. For specific explanations, see: (a) H. C. Brown and W. C. Dickason, J. Am. Chem. Soc., 92, 709 (1970); (b) D. C. Wigfield, Tetrahedron, 35, 449 (1979); (c) W. T. Wipke and P. Gund, J. Am. Chem. Soc., 98, 8107 (1976).
3. (a) E. M. Kaiser and C. R. Hauser, J. Org. Chem., 33, 3402 (1968); (b) L. H. Amundsen and L. S. Nelson, J. Am. Chem. Soc., 73, 242 (1951).
4. (a) W. N. Setzer, A. E. Sopchik, and W. G. Bentrude, J. Am. Chem. Soc., 107, 2083 (1985); (b) V. L. Boyd, G. Zon,
V. L. Himes, J. K. Stalick, A. D. Mighell, and H. V. Secor, J. Med. Chem., 23, 372 (1980).
5. J. C. Kim and Y. H. Lee, Korean J. Med. Chem., 2, 64 (1992).

## Transformation Mechanism of Bicyclic Ketal Compound to 1,5-Diketone

Sung Hoon Kim ${ }^{\dagger}$ and Jong-Gab Jun*

Department of Chemistry. Hallym University, Chunchon 200-702
${ }^{\dagger}$ Department of Chemistry, Konkuk University,
Seoul 133.701
Received January 22, 1993

The chemistry of bicyclic ketals in the 6,8-dioxabicyclo[3.2. 1]octane series are very unique and interesting. Our initial success in the preparation of 1,5 -diketone from bicyclic ketal ${ }^{1}$ expanded the utilities of this bicyclic ketal system to the direct syntheses of 2,6 -disubstituted pyridines, ${ }^{2}$ 2,3,6-trisubstituted pyridines, ${ }^{3}$ cyclohexenones ${ }^{4}$ and cyclopentanediol derivatives. ${ }^{5}$ The 1,5 -diketone is thought to be an active intermediate for these transformation reactions.
We proposed two possible mechanisms for the formation of 1,5 -diketone from bicyclic ketal using aluminium chloridesodium iodide in methylene dichloride. ${ }^{1}$ The mechanism " $a$ " in Scheme 1 involves $O(6)-C(5)$ bond cleavage followed by 1,2-hydride shift via an epoxide intermediate, whereas the alternative mechanism " $b$ " involves $O(8)-C(5)$ bond cleavage followed by proton abstraction.


Scheme 1.


Scheme 2.


Scheme 3.


Scheme 4.

Now we wish to prove the mechanism for this novel skeletal transformation of bicyclic ketal to 1,5 -diketone via deuterium labelling study.
If we have deuterium labelling at $\mathrm{C}-1$ of bicyclic ketal, it will be easy to choose the correct mechanism between " $a$ " and " $b$ " as shown in Scheme 2. The deuterated diketone must result from path " $a$ ", whereas the protonated diketone must result from path " $b$ ".
To make deuterium labelled bicyclic ketal at C-1, MVK dimer 1 was deuterated with $\mathrm{D}_{2} \mathrm{O}$ using NaOD as a catalyst (Scheme 3). We found that the less substituted site of the ketone (methyl group) is more reactive for deuterium exchange even in the thermodynamic conditions. So we deuterated all $\alpha$ and $\alpha^{\prime}$ protons to give compound 2 which was methylated with MeLi to carbinol 3 and cyclized to give expected deuterated bicyclic ketal 4.
Finally, bicyclic ketal 4 was reacted with aluminium chlo-ride-sodium iodide in methylene dichloride. The proton NMR spectrum indicated that deuterated diketone 5 was the only product; A multiplet at $\delta 2.58$ of the methine proton disappeared and methyl group at $\delta 1.09$ showed singlet. Also proton-decoupled carbon NMR spectrum showed that a singlet at $\delta 40.8$ of the methine carbon tumed to small triplet $(J=21 \mathrm{~Hz})$ (Scheme 4).
In conclusion, the mechanism for the transformation of bicyclic ketal to 1,5 -diketone must be involved $\mathrm{O}(6)$-C(5) bond cleavage followed by 1,2 -hydride shift as shown in path "a" of Scheme 1.
Acknowledgement. Financial support of the Basic Science Reasearch Institute Program, Ministry of Education (1992) is greatly acknowledged.

## References

1. J.-G. Jun, S. Suh, and D. G. Shin, J. Chem. Soc., Perkin Trans 1, 1349 (1989).
2. (a) J.-G. Jun and H, S. Shin, Tetrahedron Lett., 33, 4593 (1992); (b) J. Morris and D. G. Wishka, Tetrahedron Lett, 29, 143 (1988); (c) A. H. Lin, J. Morris, D. G. Wishka, R. R. Gorman, and N. Y. Ann, Acad. Sci., 524, 196 (1988).
3. J.-G. Jun, B. P. Mundy, T. H. Ha, K E. Bartelt, R. S. Bain, and J. H. Cardellina II, submitted.
4. (a) N. Chida, M. Ohtsuka, K. Ogura, and S. Ogawa, Bull. Chem. Soc. Japan, 64, 2118 (1991); (b) P. Duhamel, J.-M. Poirier, and G. Tavel, Tetrahedron Lett., 25, 43 (1984).
5. J.-G. Jun and H. S. Shin, Synth Commun, in press.
6. Spectral data for (2): ${ }^{1} \mathrm{H}-\mathrm{NMR}$ ( $200 \mathrm{MHZ}, \mathrm{CDCl}_{3}$ ) $\delta 4.50$ $(1 \mathrm{H}, \mathrm{td}, J=3,1 \mathrm{~Hz}, \mathrm{CH}=), 2.05-1.85\left(4 \mathrm{H}, \mathrm{m}, \mathrm{CH}_{2} \mathrm{CH}_{2}\right)$, $1.76\left(3 \mathrm{H}, \mathrm{d}, J=1 \mathrm{~Hz}, \mathrm{CH}_{3} \mathrm{C}=\right)$; ${ }^{13} \mathrm{C}$-NMR ( $\mathrm{CDCl}_{3}$ ) $\delta 210.3$ ( $\mathrm{s}, \mathrm{C}=0$ ). 150.2 (s, $\mathrm{MeC}=$ ), 96.7 ( $\mathrm{d}, \mathrm{CH}=$ ), 80.3 (small $\mathrm{t} . J=22 \mathrm{~Hz}, \mathrm{OCD}$ ), 26.5 (small m, $\mathrm{CD}_{3}$ ), $23.8\left(\mathrm{t}, \mathrm{CH}_{2}\right.$ ), 20.4 ( $\mathrm{q}, \mathrm{CH}_{3} \mathrm{C}=$ ), $19.5\left(\mathrm{t}, \mathrm{CH}_{2}\right)$.
Spectral data for (3): ${ }^{1} \mathrm{H}-\mathrm{NMR}$ ( $200 \mathrm{MHZ}, \mathrm{CDCl}_{3}$ ) $\delta 4.44$ $(1 \mathrm{H}, \mathrm{m}, \mathrm{CH}=), 2.46(1 \mathrm{H}, \mathrm{br} \mathrm{s}, \mathrm{OH}), 2.09-1.75\left(4 \mathrm{H}, \mathrm{m}, \mathrm{CH}_{2}\right.$ $\left.\mathrm{CH}_{2}\right), 1.73\left(3 \mathrm{H}, \mathrm{br}\right.$ s, $\mathrm{CH}_{3} \mathrm{C}=$ ), $1.21\left(1 \mathrm{H}, \mathrm{s}, \mathrm{CH}_{3}\right)$ and 1.18 ( $2 \mathrm{H}, \mathrm{s}, \mathrm{CH}_{3}$ ) indicates $1: 2$ ratio of diastereomer (threo: erythro); ${ }^{13} \mathrm{C}-\mathrm{NMR}\left(\mathrm{CDCl}_{3}\right) \delta 151.2(\mathrm{MeC}=), 96.0(\mathrm{CH}=)$, 81.9 (small t, $J=22 \mathrm{~Hz}, \mathrm{OCD}$ ), 26.2 and 24.5 ( $1: 2$ ratio of diastereomer for $\mathrm{CH}_{3}$, small septet of $\mathrm{CD}_{3}$ buried in this region), $22.5\left(\mathrm{CH}_{2}\right), 21.4\left(\mathrm{CH}_{3} \mathrm{C}=\right), 20.4\left(\mathrm{CH}_{2}\right)$.
Spectral data for (4): ${ }^{1} \mathrm{H}-\mathrm{NMR}\left(200 \mathrm{MHZ}, \mathrm{CDCl}_{3}\right) \delta 2.00-$ $1.45\left(6 \mathrm{H}, \mathrm{m}, \mathrm{CH}_{2} \mathrm{CH}_{2} \mathrm{CH}_{2}\right), 1.40\left(3 \mathrm{H}, \mathrm{s}, \mathrm{CH}_{3}\right), 1.36(2 \mathrm{H}$, s , endo- $\mathrm{CH}_{3}$ ); $1.26\left(\mathrm{IH}, \mathrm{s}\right.$, exo- $\left.\mathrm{CH}_{3}\right) ;{ }^{13} \mathrm{C}-\mathrm{NMR}\left(\mathrm{CDCl}_{3}\right) \delta$ 107.2 ( $\mathrm{s}, \mathrm{OCO}$ ) , 81.1 (small t, $J=26 \mathrm{~Hz}, \mathrm{OCD}$ ), 80.8 (s, $\mathrm{OCMe}_{2}$ ), $34.2\left(\mathrm{t}, \mathrm{CH}_{2}\right), 29.2\left(\mathrm{q}, \mathrm{CH}_{3}\right), 24.2\left(\mathrm{t}, \mathrm{CH}_{2}\right), 17.2$ (t. $\mathrm{CH}_{2}$ ), 25.8 and 20.9 ( $1: 2$ ratio of exo and endo $\mathrm{CH}_{3}$, small septet for $\mathrm{CD}_{3}$ also buried in the region).
Spectral data for (5): ${ }^{1} \mathrm{H}-\mathrm{NMR}\left(200 \mathrm{MHZ}, \mathrm{CDCl}_{3}\right) \delta 2.49$ $\left(2 \mathrm{H}, \mathrm{t}, J=7 \mathrm{~Hz}, \mathrm{CH}_{2} \mathrm{CO}\right), 2.46\left(2 \mathrm{H}, \mathrm{t}, J=7 \mathrm{~Hz}, \mathrm{CH}_{2} \mathrm{CO}\right)$, 2.13 ( $3 \mathrm{H}, \mathrm{s}, \mathrm{CH}_{3} \mathrm{CO}$ ), 1.83 ( 2 H , pent, $J=7 \mathrm{~Hz}, \mathrm{CH}_{2}$ ), 1.09 ( $3 \mathrm{H}, \mathrm{s}$ ); ${ }^{13} \mathrm{C}-\mathrm{NMR}\left(\mathrm{CDCl}_{3}\right) \delta 214.2$ (s, $\mathrm{C}=0$ ), 208.4 (s, $\mathrm{C}=0$ ), 42.6 (t, $\underline{\mathrm{C}}_{2} \mathrm{CO}$ ), 40.8 (small $\mathrm{t}, J=21 \mathrm{~Hz}, \mathrm{CDMe}_{2}$ ), 39.0 (t, $\mathrm{CH}_{2} \mathrm{CO}$ ), 29.8 ( $\mathrm{q}, \mathrm{CH}_{3} \mathrm{CO}$ ), 18.2 ( $\mathrm{q}, \mathrm{CH}_{3}, \mathrm{CD}_{3}$, also buried as small multiplet in this region), $17.8\left(\mathrm{t}, \mathrm{CH}_{2}\right)$.

## The Mechaniem for Cyclooligomerization of Acetylene: The Structures of $\mathrm{CpCo}\left(\mathrm{C}_{4} \mathrm{H}_{4}\right)$ and $\mathrm{CpCo}\left(\eta^{2}-\mathrm{C}_{2} \mathrm{H}_{2}\right)_{2}$ as Intermediates

Gab Yong Lee*, John B. Koerner ${ }^{\dagger}$, and Thomas A. Albright ${ }^{*}$
Department of Chemistry, Hyosung Women's University, Kyungsan 713-702
${ }^{1}$ Department of Chemistry, University of Houston, Tx 77204-5641, U.S.A.

Received January 27, 1993

A reaction of long-standing interest to the organometallic chemistry has been the trimerization of acetylene to give benzene via a number of transition metal catalysts. Despite its commercial and academic importance, there has been no prior theoretical work and several important issues are not yet resolved.

The basic mechanism ${ }^{1-3}$ is outlined in Scheme 1. An acet-ylene-ML $L_{n}$ adduct, 1, adds a second acetylene ligand to give

